Trial Profile

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lecanemab (Primary) ; Lecanemab (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms Clarity AD
Sponsors Eisai Co Ltd; Eisai Inc

Most Recent Events

03 Jul 2025 Planned End Date changed from 15 Sep 2027 to 26 May 2027.
03 Jul 2025 Planned primary completion date changed from 15 Sep 2027 to 26 May 2027.
15 Apr 2025 According to an Eisai Inc media release, the European Commission (EC) has granted the amyloid-beta monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com